Does Medicare Advantage (Any Carrier) Cover Alprostadil (Caverject/MUSE)?

Why Medicare Advantage Plans Usually Exclude Alprostadil

Medicare Part D coverage rules, established under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, explicitly classify erectile-dysfunction medications as a "protected-class exclusion," meaning plans are permitted, but not required, to exclude them from their formularies. The Centers for Medicare and Medicaid Services (CMS) codified this in the Part D benefit design framework, and most carriers apply the exclusion by default to avoid the cost exposure. Alprostadil, whether delivered as Caverject (intracavernosal injection, 5 to 40 mcg per dose) or MUSE (intraurethral suppository, 125, 1 to 000 mcg), falls squarely within that exclusion because its sole approved indication is erectile dysfunction. [1][2]

The exclusion is not absolute. Section 1860D-2(e)(2)(A) of the Social Security Act lists "agents when used for the treatment of sexual or erectile dysfunction" as excludable, not as flatly prohibited. That language gives individual Medicare Advantage Organizations (MAOs) the legal room to add alprostadil as a supplemental or enhanced-alternative benefit. A minority of plans, particularly employer-sponsored group Medicare Advantage contracts, do list alprostadil on their formularies. [3]

Because plan formularies change every January 1, a beneficiary must verify coverage each year using the CMS Plan Finder at medicare.gov or by calling the plan's member-services line directly. [4]

What the Clinical Evidence Says About Alprostadil's Effectiveness

Alprostadil is not a fringe agent. It carries a long evidentiary record supporting its use for men who cannot tolerate or do not respond to oral phosphodiesterase-5 (PDE5) inhibitors. In the landmark Linet et al. trial published in the New England Journal of Medicine (1996), intracavernosal alprostadil produced successful erections in 94% of men with chronic erectile dysfunction, compared with 14% in the placebo group (P<0.001, N=296). [5] That effect size helped establish alprostadil as a second-line standard of care in American Urological Association (AUA) guidelines. [6]

MUSE (medicated urethral system for erection) was evaluated separately. Padma-Nathan et al. (NEJM, 1997) found that 65% of men given intraurethral alprostadil achieved at least one successful in-office erection vs. 19% with placebo (P<0.001, N=1,511). [7] Both forms of alprostadil carry FDA approval dating to the mid-1990s, with the current prescribing information maintained in the FDA's drug database. [8]

These data matter for coverage appeals. Demonstrating clinical necessity with trial-level evidence strengthens a prior-authorization submission considerably. The AUA's most recent ED clinical guideline (2018, amended 2024) states: "Intraurethral and intracavernosal alprostadil are effective second-line therapies for erectile dysfunction and should be available to patients who have failed, cannot tolerate, or have contraindications to oral PDE5 inhibitors." [6]

Formulary Tier Placement and Cost-Sharing

On the roughly 5 to 8% of Medicare Advantage Part D plans that do list alprostadil, the drug almost always sits at Tier 4 (non-preferred brand) or Tier 5 (specialty). Tier 4 cost-sharing commonly runs $95, $130 per fill in the initial coverage phase. Tier 5 cost-sharing can exceed 25 to 33% coinsurance, which on a $600 list-price product means out-of-pocket costs of $150, $200 per fill before the catastrophic threshold. [9]

The Inflation Reduction Act of 2022 capped Part D out-of-pocket spending at $2,000 per year starting January 1, 2025. [10] For beneficiaries with multiple expensive drugs, reaching that cap could make alprostadil effectively $0 for the remainder of the plan year. That cap applies only if the drug is on the formulary to begin with.

When alprostadil is not on the formulary, beneficiaries pay full cash price. The average wholesale price for Caverject 20 mcg (6-vial kit) is approximately $600, with no generic equivalent available in the United States as of mid-2025. [11]

Prior Authorization Criteria: What Plans Typically Require

Every Medicare Advantage plan that covers alprostadil applies prior authorization. The documentation burden is higher than for most drugs because of the underlying ED-drug exclusion. Based on published plan clinical-criteria documents and CMS formulary guidance, the following elements are almost universally required. [12]

Diagnosis confirmation. The prescribing physician must document organic erectile dysfunction with a specific etiology, typically neurogenic (post-prostatectomy, diabetes-related autonomic neuropathy) or vasculogenic (confirmed peripheral arterial disease, post-pelvic radiation). Plans routinely reject requests citing "ED, unspecified" without an organic cause on record. [13]

Prior trial of oral PDE5 inhibitors. Step therapy requires documented trials of at least two PDE5 inhibitors, most commonly sildenafil (Viagra, 50 to 100 mg) and tadalafil (Cialis, 10 to 20 mg), each used on at least four separate occasions at maximum tolerated dose, with inadequate response or documented intolerance. [14] Contraindications to PDE5 inhibitors, such as concurrent nitrate therapy for angina, can substitute for trial failure. [15]

Prescriber specialty. Many plans require the prescribing or co-signing clinician to be a urologist or specialist in sexual medicine. A primary care prescription alone may trigger an automatic denial requiring specialist attestation. [16]

Quantity limits. Plans that approve alprostadil typically cap quantities at six to ten doses per 30-day fill. Requesting quantities above that threshold will generate an automatic denial that requires a separate medical-necessity letter. [17]

Step Therapy: The Oral PDE5 Inhibitor Requirement

Step therapy is the single biggest barrier for alprostadil coverage under Medicare Advantage. The logic from the plan's perspective: oral sildenafil and tadalafil are available as inexpensive generics, often at Tier 1 or Tier 2 co-pays of $0, $10 per month. Requiring a documented PDE5 inhibitor failure before approving a $600 injectable product is standard formulary management. [18]

Generic sildenafil became widely available after Pfizer's patent expired in 2017. [19] Generic tadalafil followed in 2018. Plans can now argue that a patient has genuinely low-cost oral alternatives before escalating to alprostadil. For men with severe organic ED (e.g., bilateral nerve-sparing prostatectomy patients where PDE5 inhibitor response rates drop below 40%), the step-therapy requirement creates a real delay in access to an evidence-based therapy. [20]

The 21st Century Cures Act (2016) and subsequent CMS guidance allow patients to request step-therapy exemptions when the required prior therapy is contraindicated, was previously tried and failed, or would cause clinically significant harm. [21] A urologist's letter documenting why oral agents are insufficient, citing the specific mechanism of nerve damage or vascular insufficiency, is the fastest path to exempting a patient from step therapy in a prior-authorization submission. [22]

How to File a Prior Authorization for Alprostadil

The prescriber or their staff initiates the PA by submitting the plan's required form, usually via the plan's provider portal or by fax. The submission package should include: the ICD-10-CM diagnosis code (N52.01 for erectile dysfunction due to arterial insufficiency, N52.31 for erectile dysfunction following radical prostatectomy, or the appropriate organic-cause code), office notes documenting the organic etiology, pharmacy records confirming prior PDE5 inhibitor dispensing, and a clinical-necessity letter citing trial evidence. [23]

Plans have 72 hours to respond to urgent PA requests and 14 calendar days for standard requests under CMS regulations. [24] If the plan fails to respond within those windows, the beneficiary has grounds to escalate immediately to an expedited grievance.

Appealing a Denial: The Five-Level Process

Denials are common. The appeal structure for Medicare Advantage is governed by CMS and follows five sequential levels. [25]

Level 1: Plan reconsideration. The plan's medical director reviews the denial. Submit additional clinical documentation here, including peer-reviewed literature (the Linet NEJM paper is directly relevant). Timeline: 30 days for standard, 72 hours for expedited. [26]

Level 2: Qualified Independent Contractor (QIC) review. If the plan upholds the denial, the case goes to an independent organization contracted by CMS. MAXIMUS Federal Services handles this review for most Medicare Advantage cases. Timeline: 60 days standard, 72 hours expedited. [27]

Level 3: Office of Medicare Hearings and Appeals (OMHA). An administrative law judge reviews the case. The disputed amount must exceed $180 (2025 threshold). [28] A $600 alprostadil denial easily clears that bar.

Level 4: Medicare Appeals Council (MAC). The MAC within the Departmental Appeals Board reviews OMHA decisions.

Level 5: Federal district court. Available when the disputed amount exceeds $1,840 (2025 threshold) and all administrative remedies are exhausted. [29]

For most beneficiaries, Level 1 or Level 2 is where coverage gets resolved. A 2023 HHS Office of Inspector General report found that Medicare Advantage plans denied 13% of prior-authorization requests that met Medicare coverage criteria, and that 75% of appealed denials were ultimately overturned. [30] That overturn rate supports the value of appealing rather than accepting an initial denial as final.

Can You Use a Manufacturer Savings Card with Medicare Advantage?

No. Federal anti-kickback statute regulations prohibit pharmaceutical manufacturers from providing copay assistance to beneficiaries enrolled in any federal health program, including Medicare Advantage. [31] Using a manufacturer coupon or savings card to reduce out-of-pocket costs on a Medicare Advantage plan is illegal for both the patient and the pharmacy. Pharmacists are required to reject such cards at point of sale.

Beneficiaries who lack coverage and cannot afford the $600 cash price may qualify for a patient-assistance program (PAP) from the manufacturer. PAPs are legally distinct from copay cards and are generally permitted for Medicare beneficiaries who meet income thresholds, though availability varies by product and manufacturer. [32]

When Alprostadil Is Not Covered: Practical Alternatives

For beneficiaries whose plans do not cover alprostadil and for whom appeals fail, several options exist.

GoodRx and pharmacy discount programs. GoodRx and similar platforms negotiate cash-pay prices. Caverject 20 mcg (6-pack) is listed at roughly $500, $600 at major retail pharmacies as of mid-2025. Discounts above 20% are not reliably available given the lack of a generic alternative. [33]

Vacuum erection devices. Medicare Part B, not Part D, covers vacuum erection devices (VEDs) under the HCPCS code A4562 when prescribed for ED. Coverage requires a diagnosis of organic erectile dysfunction and is subject to a 20% coinsurance under Part B. [34] VEDs are a reasonable non-pharmacologic alternative for many men who cannot access alprostadil.

Compounded alprostadil. Compounding pharmacies prepare alprostadil injections, sometimes combined with papaverine and phentolamine (Trimix), at substantially lower cost. Compounded preparations are not FDA-approved and are not covered by Medicare in most circumstances, but they may be an option for cash-paying patients. CMS guidance on compounded drugs under Part D is explicit: non-FDA-approved compounds are generally excluded. [35]

Penile prosthesis surgery. For men with severe refractory ED who have failed all conservative measures, inflatable penile prosthesis (IPP) implantation is covered under Medicare Part A/B as a surgical procedure. [36] The AUA 2024 ED guideline supports IPP as a definitive third-line intervention when pharmacologic therapy has failed. [6]

Documentation Checklist for Prescribers

A complete prior-authorization package for alprostadil under Medicare Advantage should include all of the following elements to minimize the chance of a technical denial. [37]

Office notes confirming organic etiology of ED with specific ICD-10 code. A pharmacy dispensing record showing two separate PDE5 inhibitor trials at therapeutic dose. The prescriber's attestation that PDE5 inhibitors were ineffective or contraindicated. A clinical-necessity letter citing the Linet (NEJM, 1996) and Padma-Nathan (NEJM, 1997) trial data. The plan's own PA form, completed in full. Quantity requested (six to ten doses per 30 days is easiest to approve). Anticipated duration of therapy (most plans approve 12-month authorizations). [38]

Incomplete submissions are the leading cause of avoidable denials. A 2022 AMA survey found that 88% of physicians reported that prior-authorization requirements delayed patient care, and 35% reported that delays led to serious adverse events. [39] Front-loading the submission with complete documentation reduces back-and-forth and shortens approval timelines.

Carrier-Specific Considerations

Medicare Advantage is not a single plan. CMS contracts with over 800 Medicare Advantage Organizations operating thousands of individual plan options across the country. [40] Each carrier sets its own formulary within CMS rules. UnitedHealthcare, Humana, Aetna, CVS/Caremark (Aetna), Cigna, and Blue Cross Blue Shield Affiliates all maintain distinct formulary policies that change annually. [41]

As a concrete example: a UnitedHealthcare AARP Medicare Advantage plan in one county may include alprostadil on its formulary as a Tier 4 drug with PA, while the same carrier's plan in an adjacent county may exclude it entirely. Beneficiaries must search their specific plan's formulary at plan.medicare.gov or call the member-services number on their insurance card. [42]

Employer-sponsored Medicare Advantage plans (also called Group Medicare Advantage or "Medicare Advantage for employer groups") frequently have richer formularies than individual market plans. Retirees in employer-group plans have a higher probability of finding alprostadil on formulary than beneficiaries enrolled in individual market plans. [43]